Stock listing

OTC:AFFY Affymax Inc Stock

Follow Affymax Inc into a list and get an email when it puts out news.

Share price · OTC:AFFY

$0.0008 USD 0.0000 (0.0%)

Close on Nov 11, 2026

Past year -11.1% · daily closes, Nov 11, 2025 – Nov 11, 2026, adjusted for splits
Day range
$0.0008 – $0.0008 USDNov 11, 2026
Volume
50,535 sharesNov 11, 2026
Market cap
$29,992 USDAt the close on Nov 11, 2026 · price × 37.49M shares outstanding
52-week range
$0.0007 – $0.0030 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
Traded on an average day
$3 USDMedian day 0 shares · 29 days with no trades · last 3 months, Aug 11, 2026 – Nov 11, 2026
Affymax Inc logo

Daily closes

Last 3 months, Aug 11, 2026 – Nov 11, 2026 · OTC:AFFY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00080.00000.0%$0.0008$0.0008$0.000850,535
$0.00080.00000.0%$0.0008$0.0008$0.0008108
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.0008170
$0.00080.00000.0%$0.0008$0.0008$0.00081,500
$0.0008-0.0008-50.0%$0.0008$0.0008$0.00083,440
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.001610,000
$0.00160.00000.0%$0.0016$0.0016$0.001610,000
$0.0016-0.0001-5.9%$0.0016$0.0016$0.00163,000
$0.0017+0.0001+6.2%$0.0016$0.0017$0.00163,200
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.0016500
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00163,350
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.0016200
$0.0016-0.0004-20.0%$0.0016$0.0016$0.0016200
$0.0020+0.0004+25.0%$0.0016$0.0020$0.00161,500
$0.00160.00000.0%$0.0016$0.0016$0.001624,000
$0.00160.00000.0%$0.0016$0.0016$0.00161,250
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.0016600
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.0016800
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.0016679
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00165,000
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.00160.00000.0%$0.0016$0.0016$0.00160
$0.0016+0.0009+128.6%$0.0016$0.0016$0.0016327
$0.00070.00000.0%$0.0007$0.0007$0.00070
$0.0007-0.0009-56.3%$0.0007$0.0007$0.0007260
$0.00160.00000.0%$0.0016$0.0016$0.00160
Ticker
OTC:AFFY
Asset type
Stock
Exchange
OTC
Currency
USD

Valuation

price Nov 11, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
-0.84

Events

QuarterResultsShare move
Quarter to Sep 30, 2024Nov 18, 2024−66.7%
Quarter to Jun 30, 2024Aug 1, 20240.0%
Quarter to Mar 31, 2024May 8, 2024+14.3%
Quarter to Dec 31, 2023Feb 28, 20240.0%
Quarter to Sep 30, 2023Nov 8, 2023+50.0%
Quarter to Jun 30, 2023Aug 3, 2023
Quarter to Mar 31, 2023May 10, 2023
Quarter to Dec 31, 2022Mar 1, 2023
Quarter to Sep 30, 2022Nov 9, 2022
Quarter to Jun 30, 2022Jul 28, 2022
All 16 quarters
QuarterResultsShare move
Quarter to Mar 31, 2022May 4, 2022
Quarter to Dec 31, 2021Mar 2, 2022
Quarter to Sep 30, 2021Nov 3, 2021
Quarter to Jun 30, 2021Jul 29, 2021
Quarter to Mar 31, 2021May 5, 2021
Quarter to Dec 31, 2020Mar 3, 2021

Open Events

Financials

Annual, in USD

Income statement

LineFY2013FY2012FY2011FY2010FY2009FY2008FY2007FY2006FY2005FY2004
Revenue1.37M94.4M47.7M112.5M114.9M82.9M44.3M11.7M74.0K151.0K
Cost of revenue11.9K45.0M75.3M93.6M191.7M170.3M92.4M69.2M33.4M21.4M
Gross profit1.36M49.4M47.7M112.5M114.9M82.9M44.3M11.7M74.0K151.0K
Research and development11.9M51.7M76.3M93.6M157.1M137.5M69.4M54.3M24.1M17.3M
Selling, general and administrative27.5M89.7M31.9M33.3M36.7M
Operating income-15.0M-92.0M-61.4M-14.4M-78.9M-88.7M-49.1M-53.7M-34.0M-22.1M
Depreciation and amortization722.0K1.99M2.18M2.21M2.12M1.29M614.0K704.0K729.0K860.0K
EBITDA-14.3M-90.1M-59.2M-12.2M-76.8M-87.4M-48.5M-53.0M-33.3M-21.3M
Interest expense1.56M1.44M144.0K140.0K105.0K609.0K14.0K84.0K29.0K0
Income before tax-16.6M-93.4M-61.4M-14.1M-77.9M-86.2M-37.7M-48.3M-32.6M-21.8M
Income tax-2.16M-26.0K1.00K1.00K-1.41M282.0K5.36M-5.42M-1.43M-720.0K
Net income-14.4M-93.4M-61.4M-14.1M-76.5M-86.5M-43.1M-48.3M-32.6M-21.4M
Earnings per share, basic-0.39-2.57-1.84-0.57-4.06-5.68-2.88-32.02-99.93-70.16

Balance sheet

LineFY2013FY2012FY2011FY2010FY2009FY2008FY2007FY2006FY2005FY2004
Cash and equivalents5.60M68.3M54.3M63.5M125.3M24.0M108.2M147.5M14.4M1.66M
Short-term investments9.72M44.2M33.6M35.3M70.7M60.1M76.8M43.5M23.1M
Receivables18.4M6.94M20.0M24.4M15.3M10.2M
Inventory3.09M
Current assets6.32M102.5M107.6M99.5M190.7M127.1M194.8M240.6M58.6M25.3M
Property, plant and equipment2.98M3.01M3.98M5.47M6.95M4.47M2.01M1.11M1.05M
Total assets7.44M118.2M119.0M131.4M211.5M167.7M225.8M250.0M61.0M27.7M
Accounts payable101.0K6.59M941.0K321.0K464.0K614.0K9.35M9.11M3.34M806.0K
Current liabilities8.87M99.1M19.8M47.6M133.7M93.4M55.7M12.0M5.38M2.15M
Long-term debt8.00K140.0K310.0K
Total debt8.84M9.19M7.00K141.0K433.0K533.0K
Total liabilities8.87M109.9M43.0M58.8M144.6M158.7M141.6M133.1M174.7M114.9M
Shareholders' equity-1.43M8.28M76.0M72.5M66.9M8.98M84.2M116.9M-113.7M-87.2M
Shares outstanding37.4M36.3M33.3M24.5M18.9M15.2M14.9M1.51M326.0K305.0K

Cash flow

LineFY2013FY2012FY2011FY2010FY2009FY2008FY2007FY2006FY2005FY2004
Cash from operations-67.3M-37.2M-72.0M-49.2M-80.9M-62.6M-45.5M68.3M-24.8M-19.9M
Capital spending0-4.06M-1.26M-730.0K-716.0K-3.78M-3.52M-1.45M-127.0K-134.0K
Free cash flow-67.3M-41.2M-73.2M-50.0M-81.6M-66.4M-49.1M66.8M-24.9M-20.1M
Cash from investing14.4M28.0M8.00M-11.5M49.2M-22.6M5.17M-43.0M-20.5M64.0K
Cash from financing-9.73M23.1M54.8M-1.08M133.0M1.09M1.04M107.8M58.0M19.9M
Share buybacks271.0K13.1M54.8M8.11M-1.00K-1.00K-45.0K-1.00K-13.0K
Change in cash-62.7M13.9M-9.16M-61.8M101.3M-84.2M-39.3M133.1M12.7M49.0K

Open Financials

Cap table

Built by 6ix from Affymax Inc’s releases

Common shares
37,490,095
Fully diluted
37,490,095

Fully diluted

LineShares
Common shares37,490,095

Share count over time

CountShares
Nov 22, 202637,490,095

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Hollings Renton
Other companies: AnaptysBio, Inc. (Director · Since at least Jan 25, 2017); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 7, 2023 · Past); Kythera Biopharmaceuticals Inc (Director · Dec 31, 2014 – Oct 1, 2015 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Rigel Pharmaceuticals, Inc. (Director · May 31, 2006 – May 15, 2013 · Past); Cepheid (Director · Apr 27, 2006 – Nov 4, 2016 · Past); Onyx Pharmaceuticals Inc (President and CEO, Director · Jan 19, 2006 – Feb 19, 2008 · Past)
Director · Jun 9, 2009 – Jun 13, 2012 · Past
John Peter Walker
Other companies: Zosano Pharma Corp (Director · May 4, 2016 – Jun 25, 2020 · Past); Renovis Inc (Director · Oct 2, 2007 – May 2, 2008 · Past); Geron Corporation (Director · May 23, 2007 – Jan 30, 2009 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2007 – Feb 2, 2011 · Past)
Director · May 31, 2007 – Aug 28, 2013 · Past
Anne-Marie Duliege
Other companies: Rigel Pharmaceuticals, Inc. (EVP & Chief Medical Officer · Mar 7, 2016 – Mar 20, 2019 · Past); ChemoCentryx Inc. (EVP, Chief of Strategic Dev. · Mar 25, 2014 – Nov 18, 2014 · Past)
Chief Medical Officer · Jan 1, 2008 – Jan 30, 2013 · Past

Open People

Log in to ask 6ix AI your own questions about Affymax Inc.